Eledon files IND for islet cell transplant trial as Phase 3 nears
Eledon Pharmaceuticals has submitted an Investigational New Drug application to the FDA for a company-sponsored registrational trial of its anti-CD40L antibody tegoprubart in pancreatic islet cell transplantation for type 1 diabetes, marking the drug's first formal regulatory step in that indication. The Irvine, California-based company simultaneously reported first patient enrolments and compassionate-use dosings across several parallel tegoprubart programmes, and reaffirmed that its global Phase 3 LEGACY trial in kidney transplantation remains on course to begin in the fourth quarter of 2026.
The IND filing follows encouraging investigator-initiated data from the University of Chicago Medicine Transplant Institute, where all 12 patients with type 1 diabetes enrolled in an ongoing tegoprubart islet cell study achieved insulin independence after transplantation. Stable graft function was observed across the cohort through a maximum follow-up of 22 months, and the drug showed no signs of nephrotoxicity, hypertension, or neurotoxicity, side effects that have long constrained the clinical use of calcineurin inhibitors such as tacrolimus, the current standard of care. UChicago Medicine has now expanded that study by three additional patients.
Expanding compassionate use
Beyond the registrational pathway, Eledon reported that the first islet cell transplant patient has been switched from tacrolimus to tegoprubart under a compassionate-use protocol due to calcineurin inhibitor-related renal dysfunction. A separate investigator-initiated study at UChicago Medicine has begun enrolling patients with both type 1 diabetes and pre-existing chronic kidney disease, a population that is particularly susceptible to tacrolimus toxicity and for whom a calcineurin inhibitor-free immunosuppression regimen would represent a meaningful clinical advance.
In kidney transplantation, a first highly sensitised patient has been dosed with tegoprubart under compassionate use at Duke University Medical Center. Highly sensitised patients carry pre-existing donor-specific antibodies that limit access to compatible organs and raise the risk of antibody-mediated rejection; this population has historically been poorly served by standard immunosuppression protocols. A third patient has also been treated in a tolerance-induction study at Massachusetts General Hospital, a programme that aims to eliminate the requirement for lifelong immunosuppression altogether.
Chief executive David-Alexandre Gros said the breadth of activity was intended to generate "important clinical insights and data updates over the next 12 months" and that the company was working to "redefine transplant immunomodulation."
Market context and competitive landscape
The transplant immunosuppression market is dominated by generic calcineurin inhibitors, principally tacrolimus and cyclosporine, which carry well-documented nephrotoxic and metabolic liabilities. The CD40-CD40L costimulatory pathway has been a target of interest for more than two decades, with early anti-CD40L antibodies shelved due to thromboembolic safety concerns. Tegoprubart is positioned by Eledon as a structurally refined successor designed to avoid those earlier complications, though confirmatory Phase 3 safety and efficacy data are still outstanding.
The LEGACY trial, which follows a successful End-of-Phase 2 meeting with the FDA, is designed to enrol approximately 600 patients with a primary composite endpoint of biopsy-proven acute rejection, graft loss, and death at 52 weeks, tested for non-inferiority versus tacrolimus. Success in LEGACY would be the pivotal data package required for a kidney transplant approval. Meanwhile, the expanding islet cell portfolio gives Eledon a potential second indication in type 1 diabetes, a disease area where the FDA's approval of encapsulated islet therapies has raised the profile of the broader field. How tegoprubart performs against emerging cell-based and gene-edited organ alternatives will be a key question for investors tracking the programme through 2027 and beyond.